« Back
Home /
740 Y-P

740 Y-P

Item no.	HY-P0175-10mM
Manufacturer	MedChem Express
CASRN	1236188-16-1
Amount	10 mMx1 mL
Quantity options	10 mMx1 mL 10 mg 1 mg 5 mg
Category	Cardiovascular Research Thrombosis & Hemostasis Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.96
Citations	[1]Derossi D, et al. Stimulation of mitogenesis by a cell-permeable PI 3-kinase binding peptide.\|[2]Xiaoli Feng, et al. Graphene Oxide Induces p62/SQSTM-dependent Apoptosis Through the Impairment of Autophagic Flux and Lysosomal Dysfunction in PC12 Cells. Acta Biomater. 2018 Nov;81:278-292.\|[3]Zhiqing Sun, et al. GABAB Receptor-Mediated PI3K/Akt Signaling Pathway Alleviates Oxidative Stress and Neuronal Cell Injury in a Rat Model of Alzheimer's Disease. J Alzheimers Dis. 2020;76(4):1513-1526. ACS Omega. 2022 Nov 16;7(47):42723-42732. Acta Biomater. 2018 Nov:81:278-292. Adv Sci (Weinh). 2025 Apr;12(13):e2410032. Aging (Albany NY). 2021 Sep 27;13(18):22502-22515. Am J Transl Res. 2021 Apr 15;13(4):2060-2076. Am J Transl Res. 2025 Mar 15;17(3):2145-2153. Ann N Y Acad Sci. 2025 Nov 24. Apoptosis. 2024 Aug;29(7-8):1185-1197. Apoptosis. 2025 Feb;30(1-2):16-34. Arch Biochem Biophys. 2023 Jul 15:743:109645. Arch Dermatol Res. 2024 Dec 5;317(1):70. Arch Pharm Res. 2021 Feb;44(2):194-204. Biochem Biophys Res Commun. 2022 May 21;605:162-170. Biochem Biophys Res Commun. 2023 Sep 3:671:246-254. Biochem Biophys Res Commun. 2024 Apr 23:149983. Biochem Biophys Res Commun. 2025 May 16:771:152037. Biochem Biophys Res Commun. 2025 Sep 8:778:152337. Biochem Pharmacol. 2024 Nov 9:116620. Biochem Pharmacol. 2025 Dec;242(Pt 3):117405. Bioengineered. 2021 Dec;12(2):12940-12953. Bioengineered. 2022 Apr;13(4):10047-10060. Biol Reprod. 2023 Nov 15;109(5):736-748. Biomater Adv. 2026 Mar:180:214576. Biomaterials. 2019 Feb;194:57-72. Biomed Pharmacother. 2020 Nov;131:110689. Biomed Pharmacother. 2024 Nov:180:117560. Bioorg Chem. 2025 Sep 16:165:109002. Bioresour Bioprocess. 2025 Jul 30;12(1):82. bioRxiv. 2023 Mar 25:2023.03.23.534007. bioRxiv. 2025 Mar 26:2025.03.24.645017. BMC Cancer. 2022 Jun 18;22(1):671. BMC Cancer. 2023 Jul 5;23(1):628. BMC Med. 2022 Dec 8;20(1):475. Bone Joint Res. 2025 Feb 6;14(2):97-110. Braz J Med Biol Res. 2024 Aug 19:57:e13796. Braz J Med Biol Res. 2025 Mar 24:58:e14408. Cancer Med. 2023 Mar;12(5):5781-5797. Cancer Rep (Hoboken). 2025 May;8(5):e70220. Cancers (Basel). 2023 Mar 28;15(7):2023. Cancers (Basel). 2025 Aug 29;17(17):2846. Carbon. 2023 Jan 25, 217, 118617. Cell Biochem Biophys. 2025 Jun;83(2):1785-1798. Cell Biochem Biophys. 2025 Jun;83(2):2023-2033. Cell Biol Toxicol. 2025 Jul 1;41(1):110. Cell Biosci. 2019 Aug 27;9:68. Cell Commun Signal. 2020 Aug 24;18(1):131. Cell Death Dis. 2021 Sep 13;12(9):845. Cell Death Dis. 2025 Jun 16;16(1):451. Cell Mol Life Sci. 2024 Mar 13;81(1):133. Cell Prolif. 2022 Sep 26;e13342. Cell Rep. 2021 Nov 16;37(7):110007. Cell Signal. 2020 Jul;71:109606. Cell Signal. 2025 Nov:135:111984. Cell Signal. 2025 Nov:135:112026. Cells. 2023 Jan 3;12(1):194. Chin Med. 2022 Sep 29;17(1):115. Clin Med Insights Oncol. 2021 May 5:15:11795549211012666. Contrast Media Mol Imaging. 2022 Jul 14:2022:2109908. Curr Eye Res. 2025 Jun 24:1-9. Curr Med Sci. 2025 Apr;45(2):253-263. Curr Med Sci. 2025 Oct 16. Curr Microbiol. 2025 Feb 3;82(3):110. Cytokine. 2022 Feb:150:155776. Cytotechnology. 2025 Apr;77(2):77. Dis Markers. 2021 Sep 1:2021:9950663. Discov Oncol. 2025 Sep 30;16(1):1789. Drug Dev Res. 2022 Aug;83(5):1152-1166. Drug Dev Res. 2022 Nov;83(7):1673-1682. Drug Resist Updat. 2024 Dec 3:78:101179. Electron J Biotechnol. 2025 Aug 13. Epigenetics. 2023 Dec;18(1):2239607. Eur J Histochem. 2025 Jun 17;69(3). Eur J Pharmacol. 2023 Sep 5:954:175863. Eur J Pharmacol. 2024 Apr 5:968:176401. Eur J Pharmacol. 2024 Sep 10:176824. Eur J Pharmacol. 2024 Sep 10:176991. Exp Cell Res. 2019 Dec 15;385(2):111691. Exp Eye Res. 2023 Jan:226:109335. Exp Mol Med. 2023 May;55(5):939-951. Exp Ther Med. 2021 Sep;22(3):1017. Fish Shellfish Immunol. 2022 Jan:120:648-657. Folia Neuropathol. 2025 Apr 4. Food Chem Toxicol. 2025 Oct:204:115664. Free Radic Biol Med. 2023 Oct 10;209(Pt 1):55-69. Front Biosci (Landmark Ed). 2024 Aug 19;29(8):289. Front Pharmacol. 2020 Feb 25;11:114. Front Pharmacol. 2021 Jul 15:12:667644. Gene Ther. 2024 Nov;31(11-12):594-606. Genes (Basel). 2023 Apr 20;14(4):944. Genes Dis. 2021 Jul 1;9(6):1650-1661. Genome Med. 2025 Sep 25;17(1):102. Genomics. 2023 Jul;115(4):110636. Glia. 2023 Mar;71(3):720-741. Heliyon. 2024 Aug 20;10(17):e36579. Heliyon. 2024 Jul 10;10(14):e34397. Heliyon. 2024 Jun 10;10(12):e32802. Heliyon. 2024 May 31;10(11):e32230. In Vitro Cell Dev Biol Anim. 2022 Jun;58(6):491-502. Inflammopharmacology. 2023 Feb;31(1):369-384. Int Immunopharmacol. 2023 Sep 5;124(Pt A):110876. Int Immunopharmacol. 2023 Sep:122:110579. Int Immunopharmacol. 2024 Jul 26:139:112717. Int Immunopharmacol. 2024 May 17:134:112241. Int Immunopharmacol. 2024 May 30:133:112005. Int Immunopharmacol. 2025 Apr 4:151:114352. Int Immunopharmacol. 2025 Aug 3:163:115304. Int J Biol Macromol. 2023 Jul 31:244:125373. Int J Biol Macromol. 2024 Sep 10:135547. Int J Biol Macromol. 2025 Jan 10:139766. Int J Biol Sci. 2025 Aug 11;21(12):5206-5222. Int J Gen Med. 2025 Sep 19:18:5699-5716. Int J Mol Med. 2021 Feb;47(2):688-698. Int J Mol Med. 2021 May;47(5):67. Int J Mol Med. 2023 May;51(5):40. Int J Mol Med. 2025 Nov;56(5):194. Int J Mol Sci. 2023 May 19;24(10):9000. Int J Mol Sci. 2024 Dec 25;26(1):84. Int J Oncol. 2021 Jul;59(1):42. Int J Oncol. 2021 May;58(5):23. Ir J Med Sci. 2023 Apr;192(2):561-567. iScience. 2024 Jan 17;27(2):108926. J Agric Food Chem. 2022 Dec 21;70(50):15804-15817. J Agric Food Chem. 2025 May 14;73(19):11730-11755. J Biochem Mol Toxicol. 2025 Apr;39(4):e70210. J Cell Mol Med. 2024 Jul;28(13):e18386. J Cell Physiol. 2024 Jun;239(6):e31259. J Clin Invest. 2023 Jan 17;133(2):e153470. J Clin Lab Anal. 2022 Dec;36(12):e24720. J Colloid Interface Sci. 2025 Oct 8;703(Pt 2):139206. J Control Release. 2025 Oct 22;388(Pt 2):114350. J Dairy Sci. 2022 Apr;105(4):3405-3415. J Ethnopharmacol. 2021 Dec 5:281:114438. J Ethnopharmacol. 2024 Mar 25:322:117628. J Ethnopharmacol. 2024 May 10:325:117768. J Ethnopharmacol. 2025 Jan 18:119381. J Ethnopharmacol. 2025 Jan 30;337(Pt 2):118910. J Exp Clin Cancer Res. 2020 Jun 30;39(1):123. J Exp Clin Cancer Res. 2021 Aug 12;40(1):255. J Funct Foods. 2023 Oct, 109, 105770. J Gastroenterol Hepatol. 2025 Aug;40(8):1991-2006. J Headache Pain. 2022 Aug 10;23(1):98. J Hepatocell Carcinoma. 2021 Nov 3;8:1323-1338. J Inflamm Res. 2025 Aug 3:18:10389-10402. J Integr Med. 2025 Sep 4:S2095-4964(25)00137-2. J Mol Histol. 2023 Dec;54(6):621-631. J Nutr Biochem. 2022 Feb:100:108882. J Nutr Biochem. 2024 Jul 16:109702. J Pharm Pharmacol. 2022 Sep 1;74(9):1251-1260. J Steroid Biochem Mol Biol. 2025 Jul 3:254:106825. J Transl Med. 2021 Feb 10;19(1):62. J Transl Med. 2023 Nov 16;21(1):817. J Transl Med. 2024 Nov 29;22(1):1085. Kaohsiung J Med Sci. 2025 Nov 5:e70131. Korean J Physiol Pharmacol. 2022 Nov 1;26(6):541-556. Life Sci. 2019 Sep 15:233:116696. Life Sci. 2021 Nov 1:284:119107. Mater Today Bio. 2022 Jul 1;16:100344. Mol Biol Rep. 2023 Jan;50(1):687-696. Mol Cancer. 2022 May 10;21(1):112. Mol Cell Biochem. 2022 Jul;477(7):1947-1957. Mol Cell Biochem. 2022 May;477(5):1541-1553. Mol Cell Proteomics. 2023 Sep;22(9):100628. Mol Cell. 2025 Apr 3;85(7):1411-1425.e8. Mol Immunol. 2025 Sep:185:27-38. Mol Med Rep. 2021 Jan;23(1):76. Mol Med. 2023 Oct 3;29(1):133. Mol Neurobiol. 2025 Mar;62(3):3615-3629. Nat Commun. 2024 Sep 12;15(1):7996. Naunyn Schmiedebergs Arch Pharmacol. 2024 Feb;397(2):1003-1013. Neurogastroenterol Motil. 2020 Oct;32(10):1514-1528. Neuropharmacology. 2025 Nov 15:279:110631. Noncoding RNA Res. 2024 Nov 12. Onco Targets Ther. 2019 Dec 4;12:10639-10650. Oncol Lett. 2021 Dec;22(6):812. Oncol Lett. 2023 Apr 13;25(6):224. Oncol Lett. 2023 Nov 15;27(1):17. Oncol Rep. 2020 Mar;43(3):919-929. Oncol Rep. 2021 May;45(5):63. Oncol Rep. 2022 Oct;48(4):169. OncoTargets and Therapy Dovepress. 2019 Oct 16;12:8537-8552. Oral Dis. 2024 Oct;30(7):4231-4242. Oxid Med Cell Longev. 2021 Mar 30:2021:6661534. Pathol Res Pract. 2023 Sep:249:154717. Pharm Biol. 2022 Dec;60(1):75-86. Pharmaceuticals (Basel). 2025 Sep 16;18(9):1378. Phytomedicine. 2022 May:99:154014. Phytomedicine. 2022 Oct:105:154360. Phytomedicine. 2023 Dec:121:155117. Phytomedicine. 2023 Jul 25:116:154873. Phytomedicine. 2025 May:140:156498. Phytother Res. 2023 Aug;37(8):3572-3582. Phytother Res. 2024 Jul;38(7):3509-3524. PLoS One. 2024 Oct 16;19(10):e0311419. PLoS One. 2024 Sep 27;19(9):e0311143. Research Square Preprint. 2023 Apr 13. Research Square Preprint. 2023 Aug 10. Research Square Preprint. 2024 Mar 25. Research Square Preprint. 2024 May 2. Research Square Print. 2022 May. Respir Physiol Neurobiol. 2020 Oct;281:103496. Sci Rep. 2021 Sep 29;11(1):19268. Sci Rep. 2023 Jul 21;13(1):11795. Sci Rep. 2024 Aug 30;14(1):20231. Sci Rep. 2024 Sep 5;14(1):20802. Sci Rep. 2025 Apr 19;15(1):13539. Sci Rep. 2025 Mar 20;15(1):9644. Sci Rep. 2025 Mar 4;15(1):7639. Sci Rep. 2025 May 9;15(1):16205. SSRN. 2025 Sep 19. Technol Cancer Res Treat. 2020 Jan-Dec:19:1533033820957023. Theranostics. 2024 Jul 8;14(11):4278-4296. Toxicol Appl Pharmacol. 2020 Dec 15;409:115335. Toxicol Appl Pharmacol. 2022 Apr 15:441:115971. Toxicol In Vitro. 2022 Apr;80:105328. Tradit Med Res. 2020 May. Viruses. 2023 Jul 28;15(8):1646. World J Gastrointest Oncol. 2023 Oct 15;15(10):1739-1755. BMC Complement Med Ther. 2023 Aug 22;23(1):295.
Smiles	C([C@@H](C(N[C@@H](CC1=CC=CC=C1)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CC=2C=3C(NC2)=CC=CC3)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(NCC(N[C@@H](CC4=CC=C(OP(=O)(O)O)C=C4)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(O)=O)CO)=O)CCSC)=O)CC(O)=O)=O)CCSC)=O)=O)=O)=O)CC(O)=O)=O)CO)=O)CCCCN)=O)CCCCN)=O)=O)CCCCN)=O)CCSC)=O)CCCNC(=N)N)=O)CCCNC(=N)N)=O)CC(N)=O)=O)CCC(N)=O)=O)=O)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CCCNC(=N)N)N)=O)CCC(N)=O)=O)[C@H](CC)C)=O)CCCCN)=O)[C@H](CC)C)=O)C=5C=6C(NC5)=CC=CC6
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	740YPDGFR,PDGFR 740Y-P
Shipping Condition	Cool pack
Available
Manufacturer - Type	Peptides
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Category	Peptides; Reference compound / Active compounds; Cell-penetrating Peptides
Manufacturer - Targets	Autophagy; PI3K
Shipping Temperature	Blue Ice
Storage Conditions	-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)
Molecular Weight	3270.70
Product Description	740 Y-P (740YPDGFR; PDGFR 740Y-P) is a potent and cell-permeable PI3K activator. 740 Y-P readily binds GST fusion proteins containing both the N- and C- terminal SH2 domains of p85 but fails to bind GST alone[1].
Manufacturer - Research Area	Cancer
Solubility	H2O : 10 mg/mL (ultrasonic)
Manufacturer - Pathway	Autophagy; PI3K/Akt/mTOR
Clinical information	No Development Reported
Isoform	PI3K
UNSPSC Code	12352209

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.